Bard Davol
Davol, founded in Providence, RI in 1874, initially provided the medical community with hot water bottles and catheters. Over the past 40 years, Davol has established itself as the market leader in soft tissue reconstruction solutions, specializing in hernia repair, surgical procedures, fixation, and biologic implants.
As a subsidiary of C.R. Bard, Inc., Davol maintains its leadership position in the medical device industry, offering a diverse portfolio of proven, innovative solutions. These include mesh prosthetics, biologic implants, surgical instruments and techniques for various hernia repair procedures, as well as products for autotransfusion, hemostasis, laparoscopy, hysteroscopy, pulsed lavage, and wound management.
With a focus on expanding their range of soft tissue repair, hemostasis, and performance irrigation products, Davol is committed to providing exceptional reliability and value, qualities that clinicians, physicians, and patients have come to depend on.
Given its extensive history and continued innovation, Bard Davol demonstrates a strong potential for growth and further development within the Health Care industry, presenting an intriguing opportunity for potential investors seeking to contribute to advancements in medical technology.
There is no investment information
No recent news or press coverage available for Bard Davol.
We care about your data, and we'd love to use cookies make your experience better.